The 65 kD isoform of Glutamic Acid Decarboxylase (GAD), is one of the major autoantigens in human type 1 diabetes mellitus. This enzyme shares aminoacid identity, in select regions already determined as antigenic with its counterpart from E. coli. We tested the reactivity of diabetic and normal sera and an E. coli GADspecific monoclonal antibody (2D9) to E. coli GAD by solid phase and competition ELISA, as well as immunoblotting to check for cross-reactivity of autoantibodies to the two antigens. Specific antibodies for E. coli GAD are present in diabetics and normal subjects without any differences in frequency and titer. The reactivity of such antibodies in ELISA could be blocked in a dose-dependent manner by the addition of excess antigen in the liquid phase. Furthermore, the monoclonal antibody against E. coli GAD does not recognise human recombinant GAD65 in an ELISA. We conclude that there is no basis for cross-reactivity between the two antigens, and antibody reactivity to GAD65 in man cannot arise from cross-reactivity to the E. coli enzyme.
Glutamic acid decarboxylase (GAD) is the enzyme converting glutamate to a-amino butyric acid (GAB A) and CO 2 , In mammals there are two isoforms of GAD, of molecular weight 65 and 67 kD. GAD65 is one of the major autoantigens in insulin dependent diabetes mellitus (lDDM) (1) , an autoimmune disease characterized by the destruction of the insulin-producing islet f3-cells in the pancreas, while few IDDM patients show reactivity towards the GAD67 isoform (2, 3) . Antibodies against GAD are detected in sera of patients, and also in animal models of the disease, such as the non-obese diabetic (NOD) mice and the Bio-Breeding (BB) rats (4, 5) . E. coli GAD and mammalian GAD belong to the family of pyridoxal phosphate (PLP)-dependent decarboxylases, but they share with each other only a low (about 20% identity) degree of homology (2, 6) . However, E. coli GAD contains many (40% identity) of the conserved residues of the PLP binding site, and the 240-250 region (50% identity), which is within the carboxy-terminal two-thirds of the molecule (2, 5) . In human GAD65 this carboxyterminal region is shown to contain the epitopes recognised by antibodies from the sera of diabetic patients (3) . The bacterial enzyme from E. coli is an hexameric protein of MW ca. 310 kD, consisting of 6 subunits, 50 kD each (7) . There are actually two genes of the bacterial enzyme encoded in distinct genetic loci, yet different in only 5 aminoacid residues, four of which are in the amino-terminal. (8) . The kinetic and functional properties of these two enzymes are identical (8) . The enzyme is widely distributed and found in most strains of E. coli (9) . It was shown previously that BB rats immunised with E. coli GAD developed specific MHC-restricted T-cell clones (10) , and that oral administration of the E. coli enzyme led to immunomodulation of anti-GAD immunity in mice where diabetes was induced by multiple low doses of streptozotocin (II), a treatment known to lead to insulitis (12) . There arose thus a question about the role of E. coli GAD in the disease process, perhaps through molecular mimicry (13) . Molecular mimicry has often been postulated as a probable cause of autoimmune disease, spontaneous and experimentally-induced, yet to date there have been few examples of disease due to mimicry, but rather several cases of cross-reactivity at the antibody and T cell level (14) (15) (16) (17) (18) . The bacterium E. coli is found under normal conditions in the human intestine, and an immune response to E. coli antigens is not uncommon (19) . Molecular mimicry has been postulated as a mechanism through which misdirected immune response to microbial pathogens could give rise to autoimmunity both in the humoral and cellular compartments (20) .
In order to investigate the possible role of E. coli GAD in IDDM pathogenesis we tested the reactivity of sera from newly diagnosed diabetic and normal subjects against this molecule using enzyme linked immunosorbent assay (ELISA) and an immunoblot assay. As a positive control we also generated from Balb/c mice a monoclonal antibody against E. coli GAD with the electrofusion technique.
While the monoclonal antibody reacted to E. coli GAD in ELISA and immunoblot assays, there was no reactivity of the McAb to human GAD65 in ELISA. Conversely, sera from newly diagnosed IDDM patients recognized E. coli GAD in an ELISA or in immunoblot without any increase in specificity or incidence of reactivity. The unusually high content of E. coli GAD in basic and acidic arninoacids, often concentrated in stretches of two or three consecutive likely charged residues, necessitated an ELISA assay performed in high (0.5 M) NaCI, that revealed the nature of the non-specific binding of immunoglobulins from normal and diabetic sera or irrelevant monoclonal antibodies. The specificity ofantibody binding was demonstrated by competition between the soluble and solid-phase-coated E coli GAD antigen to the diluted sera. We conclude that there does not seem to be a basis for the hypothesis of immune mimicry between E. coli GAD and human GAD, as suggested by the earlier work on BB rats (10) .
MATERIALS AND METHODS
Reagents: Purified E. coli GAD was purchased from Worthington Biochemical Corporation (NJ, USA). Human recombinant GAD65 was a gift from Professor Ake Lernmark (University of Washington, Seattle, USA). All other reagent-grade chemicals were purchased from Sigma Chemical Company (St. Louis, MO, USA).
Animals: Two to three month-old female and Balb/ c mice were used for immunizations. They were kept in our animal house under specific pathogen-free conditions. Human serum samples: Human type I diabetic sera from 14 newly-diagnosed patients ( ages 6-14 years old (mean age 9.5 +/-2.5 yrs, 7 male, 7 female, samples obtained 1-6 months after disease diagnosis) and sera from 14normal subjects ofthe same age and sex distribution were generously offered by Dr. Chr. Bartsocas, P.& A. Kyriakou Children's Hospital, Athens, and by Dr. D. Mamouris from the Division of Internal Medicine, University of Ioannina Regional Hospital. The subjects were all native Greeks born in Greece. All patients were receiving insulin therapy and were in the "honeymoon" phase of the disease.
Immunization: Thirty I-Lg of E. coli GAD/mouse were injected intraperitoneally, in four 2-3 month old mice, 5 times during a period of3 months (i.e. once every three weeks) first in complete and subsequently in incomplete Freund's adjuvant. The antibody development was measured by ELISA assay in serum samples. The last boost was given intraperitoneally in PBS. Three days after the last boost, the spleen was excised and spleen cells were obtained, by maceration of the organ, for electrofusion.
ELISA: E. coli GAD was coated in immunoplates (Nunc, Roskilde, Denmark), at I u.g/rnl in carbonate/ bicarbonate buffer pH 9.6 for 2 hours in 37"C or in 4"C overnight. Blocking was achieved with 1% BSA in PBS for I hour in 37 nC. After three washings with PBS-0.05% Tween 20, serum samples, hybridoma supernatants or ascitic fluid were allowed to react with the antigen for 2 hours in 37"C. The incubation was followed by three washings with PBS-0.05% Tween 20, and then addition of the primary antibody properly diluted, and subsequently an alkaline phosphatase conjugated antibody (anti-mouse IgG, anti-mouse IgM (Sigma) or anti-human IgG ('Ychain specific (Seralab). After a 2-hour incubation the plates were washed and p-nitrophenyl phosphate was added in 10% diethanolamine buffer (pH 9.8). Development of color after substrate incubation was measured at 405 nm in a Dynatech ELISA reader MR600. As controls for the mouse IgM monoclonal antibody in ELISA and Immunoblot assays we used two irrelevant monoclonal mouse IgM antibodies, 2F8 and B2D6, directed to the surface of the rat insulinoma cells INS-I, which do not express GAD65 on their surface (21) . All the samples were also subjected to an ELISA assay where the NaCI concentration in the diluent for the primary antibody and the antibody conjugate contained 0.25 M, or 0.50 M NaCl, instead of the physiologically relevant concentration of 0.145 M. The ELISA competition assay was performed as follows: various amounts of E. coli GAD were added to the diluted serum samples and the contents were kept in Eppendorf tubes overnight at 4"C. They were added during the next day to the Ag-coated and BSA-blocked ELISA plates, side-by-side with serum samples to which no antigen was added. The steps from there on were as in the ordinary ELISA for serum antibody reactivity to E. coli GAD. From the diluted serum incubation step onwards, all solutions used were 0.25 M, or 0.5 M in NaCI.
Electrofusion: The electrofusion procedure was essentially that previously described with modifications (22) . Spleen cells and mouse myeloma NSO cells were mixed in a ratio 2: I and incubated in 0.5 mg/ml Pronase E for at most 15 min. The cells were then washed and suspended in the hypoosmotic medium 75L3 (75mM Sorbitol) (22) . The cells were subsequently placed in the BTX Meander Fusion Chamber which was connected to the BTX Electrocell Manipulator ECM 200 (BTX, San Diego CA, USA). The intensity of AC field before fusion was 720 VIcm for 7s (alignment period) with I MHz frequency. The applied DC field was 4 kV/cm, I pulse for 30 I-Ls. AC field after DC was as above. The cells were washed in HT (hypoxantine-thymidine, see below) medium and cultured for 24 hours in HT medium, consisting of DMEM without pH indicator and thereafter in "HAT medium" with pH indicator consisting of: Iscove' s Modified Dulbesco's Medium (Gibco), supplemented with NCTC Hybrimax (5%), Insulin at l u.g/rnl (Sigma), hrIL-6 (I UI ml) (R&D systems, Minneapolis MN, USA), Hypoxanthine (10-4 M), Thimidine (1.6xlO-5 M), Aminopterin (4xI0-7 M), and 20% Fetal Calf Serum (Seralab). Thirteen to eighteen days post fusion a screening was made of emerging clones for anti-E. coli GAD antibody production, by the ELISA assay.
Electrophoresis: SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was performed according to Laemmli (23) . Ten I-Lg of E. coli GAD were loaded in each well.
lmmunoblot: Samples of E. coli GAD after SDS-PAGE were transferred to nitrocellulose or PVDF membranes according to Towbin (24) . In the Immunoblot assay the culture supernatants were used in dilutions of I :4, the ascites fluid in I :2000 and human sera in 1:400. Detection of reactivity was monitored by color formation from the alkaline phosphatase substrate Brorno-Chloro-Indoyl-Phosphate in combination with Nitro Blue Tetrazolium.
RESULTS
The immunization of four Balb/c mice with E. coli GAD resulted in antibody development in their sera as determined by ELISA (data not shown). The spleen of the mouse with the highest serum titer was excised and spleen cells were fused with cells from the myeloma cell line NSO. From 30 x 10 6 spleen cells 10 primary clones were produced, one of which (209) was positive for E. coli GAD in an ELISA and an immunoblot assay (data not shown). This positive clone was subjected to two rounds of cloning by the limiting dilution method. For large scale monoclonal antibody production we injected the hybrids into Balb/c mice for the development of ascites. Culture supernatants and ascitic fluid were reactive with E. coli GAD in Immunoblot assay ( Fig. I) . Anti-E. coli GAD monoclonal antibody reacted in Immunoblot with almost all the fragments of the molecule that appeared after electrophoresis; the chief reactivity however was to the 50 kD subunit of the molecule. The monoclonal antibody was found to be an IgM antibody by isotype ELISA. The hybrid clone has been stable in culture for a period more than 12 months.
The mouse monoclonal IgM antibody against E. coli GAD reacted well with the target antigen in an ELISA assay ( Figure 2 ). However, while we observed no reactivity of the normal mouse serum IgM component to E. coli GAD, we repeatedly found a remarkably high reactivity against E. coli GAD of two irrelevant monoclonal mouse IgM antibodies, directed to the surface of rat INS-l insulinoma cells (25) . By contrast, the mouse anti-E. coli GAD monoclonal antibody did not react at all with the surface of the INS-l cells (data not shown). Therefore, we considered the E. coli GAD antigen as the source of this spurious cross-reactivity. On closer inspection of the primary stucture of E. coli GAD we noticed an unusually high proportion of acidic and basic residues with many likely charged residues in sequences of 2-4 grouped together (4) . Therefore, we opted for an ELISA assay with higher NaCI concentrations in the antibody diluent, as previously performed for the very acidic mammalian protein parathymosin (26) , Indeed, the IgM monoclonal antibodies to the surface of INS-I cells showed a dramatic drop in reactivity at three different dilutions, when the NaCI concentrarion of the antibody diluent was increased from 0.145 M, to 0.25 M and finally to 0.5 M (Fig. 2) . In fact, at 0.5 M salt concentration the difference in reactivities between the E. coli GAD monoclonal and any of the other two IgM monoclonals is very significant (2.5-1Ox the optical density at 405 nm, depending on the antibody dilution).
Having established conditions under which spurrious cross-reactivity to E. coli GAD was eliminated, we then tested sera from normal persons and newly-diagnosed diabetics for such reactivity in an ELISA under such conditions. Fourteen serum samples from newly-diagnosed 100M patients and an equal number of normal subjects of the same age, were tested. There was an almost equal extent of reactivity by normal and diabetic sera to E. coli GAD (Fig. 3 ). In the immunoblot assay sera from thirteen 100M patients and eight normal subjects showed positive reaction to the various fragments of E. coli GAD when the antibody diluent contained 0.145 M NaCI (Fig. 4 and 5) . The extensive reactivity by normal and diabetic immunoglobulin evidenced against denatured E. coli GAD in immunoblots is little affected by the increase in NaCI concentration up to 0.5 M (data not shown). Furthermore, the competition ELISA performed at the same high NaCl concentration, showed that in most sera, both from normal and diabetic subjects, the anti-E. coli GAO reactivity could be competed by increasing concentrations of the specific antigen in the liquid phase ( Fig. 6 and 7) . In many cases, particularly from the group of patients, the inhibition was dosedependent to a large extent. These results clear!y show that most humans, develop antibodies against E. coli GAO perhaps by exposure to the antigen during early childhood, as E. coli is a symbiotic bacterium in the human intestine. The specific antigenicity of the molecule is a common feature in 100M patients and normal subjects, thus no relationship seems to exist between bacterial GAO and 100M in man.
DISCUSSION
We have presented here evidence for the lack of any specific reactivity GAO by diabetic sera towards E. coli glutamic acid decarboxylase. The enzyme from E. coli is very stable, in contrast to its mammalian counterpart, and shares only low (ca. 20%) homology with rat, porcine, murine or human GA065 or 67 (ref. 4). Nonetheless, there exist two regions within the carboxy-terminal two-thirds of the molecule (80% identity in the region 370-380 of rat/human GA067 (and 361-371 of the GA065 counterpart) with 240-250 of E. coli protein, and 44% identity in the PLP binding site: region 398-406 of rat/human GA067 (and 389-397 of the GA065 counterpart) with region 269-277 of the E. coli protein. GA065 is one of the major autoantigens in 100M. Painstaking investigations lasting several years established four major autoantigens in type 1 diabetes, three of which are proteins (GA065, insulin, and a tyrosyl phosphatase-like molecule, termed IA-2, which comes in two subtypes) and the other an islet-specific ganglioside, G M2 . 1 (1, (26) (27) (28) (29) . For all three proteins it has been shown that the specific antibodies detected in diabetic patients are directed to conformational rather than linear epitopes; in GA065 the epitopes are found in the middle and last third of the molecule (1), and in IA-2 in the cytoplasmic region of this membrane protein that comprises the last (carboxy-terminal) third of the molecule (27) . Furthermore, the specific autoantibodies to insulin, in the sera of newlydiagnosed type I diabetic patients can only be detected by liquid phase R.l.A. methodology, indicative of the conformational nature of the epitope(s) (27) . There are two other disease entities that have autoantibodies recognising linear antigenic determinants on GA065, i.e. those of stiff-man syndrome (1) and autoimmune polyendocrine syndrome (31) . As a rule these autoantibodies are also of extremely high titer, which is not the case with frank 100M sera (1, 5, 31) .
The existence of a monoclonal antibody from mice that recognises E. coli GAO and its comparison with irrelevant isotype-specific monoclonal antibodies revealed another property of the E. coli enzyme, i.e. its ability to bind non-specifically to antibodies because of the unusually large content in charged aminoacids (4) . We dealt with this problem by performing ELISA assays against this molecule in a medium containing increased (up to 0.5 M) concentrations of salt, as we had previously done for the acidic polypeptide parathymosin (26) . The specificity of the reactivity of this monoclonal antibody was revealed at this high salt concentration. The two irrelevant isotype-specific monoclonals 2F8 and B206, were very specific for their target (membrane of rat insulinoma INS-I cells as shown by flow cytometry) (24) , while the E. coli GAO monoclonal 209 showed no reactivity at all towards the INS-l cells (data not shown). Therefore, each of the three IgM monoclonal antibodies is specific under stringent conditions, towards a particular target (E.coli GAO or INS-l cell membrane) with no reactivity towards the other target. In a separate set of experiments we showed that INS-I target cells do not express GA065 on their surface (Konidaris and Papadopoulos, unpublished results). We are thus dealing with bonafide antibodies, and not any aspecific antibodies that may be binding to any targets regardless of speci ficity . We then performed the ELISA assays from 14 new 1y-diagnosed diabetic and 14 normal persons at the same salt concentrations as with the monoclonal antibodies (0.14, 0.25 and 0.50 M), and found that at none ofthese concentrations was there a significant difference in reactivity between sera from diabetics and those from controls. While it is true that the mammalian GAO enzyme is unstable even for limited periods of time at room temperature, and thus all attempts to devise solid phase ELISA assays for mammalian GA065 have met with limited success (lower specificity and sensitivity than liquid phase assays with newly prepared invitro translated radiolabelled protein) (30) , this is not the case with the enzyme from E. coli (4, 5) . Thus, any conformational epitopes common to the E. coli and human enzymes, would be preserved and apparent in an ELISA assay of the bacterial enzyme as devised by us. The lack of such specific reactivity can only mean that such epitopes are not at all present in the GAD enzyme from E. coli. The specific nature of the serum antibodies against E. coli GAD was further revealed by the dose-dependent competition for antigen binding in solid vs. liquid phase ELISA. This competition was seen with most sera, from normals or diabetics, regardless of the titer. The nature of the epitopes recognised remains to be determined, as well as the original stimulus for the production of antibacterial antibodies of significantly high titer. There seems however to be little cross-reactivity of these anti-E. coli GAD antibodies towards human GAD65, as all the sera from normal subjects in the Greek population were negative for anti human GAD65 antibodies in a very sensitive liquid phase ELISA (Mamouris, Borch, Petersen and Papadopoulos, unpublished results). Reactivity of sera from patients of long duration is a subject of further investigation. It is also known that anti-GAD65 reactivity in diabetic patients is of long duration (32) .
In theories of molecular mimicry as the triggering event for autoimmunity, there is also the possibility of self-reactivity at the T cell level. The residues of a peptide antigenic epitope can be divided into those that make contact with the major histocompatibility complex molecule (anchor residues) and those that make contact with the cognate T cell receptor (aggretope residues) (14, 16, 18, (33) (34) (35) . Mimicry in this case must extend to both categories of residues, particularly the latter; there are several cases where substitutions with slightly different residues lead to remarkable changes in the binding of the peptide to the MHC molecule, or the response of cognate T cells (16-18; 36-41) . It turns out however, that E. coli GAD does not have any octamer or nonamer aminoacid stretches (minimal epitopes for MHC class I and class II binding) that are appreciably homologous to human GAD65, so the possibility of cross-reactivity at the T cell level must also be ruled out (4) . The E. coli GAD-specific T cell clones obtained from BB rats after immunization were never tested, to our know ledge for proliferation to mammalian GAD (10) . The search for causative agents for autoimmune diseases will continue, no doubt, yet any hypotheses must be rigorously tested by available techniques of immunochemistry, as done here, before proceeding to misleading generalizations. We particularly draw attention to performance of immunochemical assays under higher than physiological salt concentrations as one means to eliminate non-specific effects that may originate from excess electric charges on the antigen or antibody (26) . We further conclude that the search for a causative agent for type 1 diabetes in the context of molecular mimicry must focus on proteins other than E. coli GAD.
